AbCellera Biologics Inc (ABCL)
3.895
-0.09
(-2.26%)
USD |
NASDAQ |
Apr 24, 16:00
3.895
0.00 (0.00%)
After-Hours: 16:03
AbCellera Biologics Profit Margin (Quarterly): -513.7% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -513.7% |
| September 30, 2023 | -433.6% |
| June 30, 2023 | -303.6% |
| March 31, 2023 | -329.0% |
| December 31, 2022 | -138.7% |
| September 30, 2022 | 26.26% |
| June 30, 2022 | -14.78% |
| March 31, 2022 | 53.25% |
| December 31, 2021 | 43.03% |
| Date | Value |
|---|---|
| September 30, 2021 | -388.2% |
| June 30, 2021 | -8.40% |
| March 31, 2021 | 57.82% |
| December 31, 2020 | 56.28% |
| September 30, 2020 | -28.77% |
| June 30, 2020 | 59.70% |
| March 31, 2020 | -44.94% |
| December 31, 2019 | -51.24% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-513.7%
Minimum
Dec 2023
59.70%
Maximum
Jun 2020
-115.2%
Average
-28.77%
Median
Sep 2020
Profit Margin (Quarterly) Benchmarks
| Acasti Pharma Inc | -- |
| Aurinia Pharmaceuticals Inc | -59.60% |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | -448.0% |
| InMed Pharmaceuticals Inc | -119.2% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -12.26% |
| Return on Assets | -9.66% |
| Return on Invested Capital | -12.26% |
| Operating Margin (Quarterly) | -682.8% |
| Return on Net Operating Assets | -27.58% |